We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.78%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.01B
AUM Growth
+$119M
Cap. Flow
-$210M
Cap. Flow %
-2.99%
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$40.7M
2
LLY icon
Eli Lilly
LLY
+$35.4M
3
MRK icon
Merck
MRK
+$34M
4
HUM icon
Humana
HUM
+$29.6M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$29.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$57.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$51M
3
BSX icon
Boston Scientific
BSX
+$40.6M
4
HCA icon
HCA Healthcare
HCA
+$39.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Industrials 0.87%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
76
DELISTED
ESSA Pharma
EPIX
$21.3M 0.3%
7,898,583
– –
GBIO
77
DELISTED
Generation Bio
GBIO
$19.9M 0.28%
362,028
– –
PHR icon
78
Phreesia
PHR
$662M
$19.8M 0.28%
638,653
– –
CNC icon
79
Centene
CNC
$32.8B
$19.7M 0.28%
292,527
-256,814
-47% -$17.1M
SUPN icon
80
Supernus Pharmaceuticals
SUPN
$2.79B
$19.5M 0.28%
650,256
+527,375
+429% +$18.5M
LEGN icon
81
Legend Biotech
LEGN
$4.31B
$19M 0.27%
275,754
-231,500
-46% -$15.1M
TXG icon
82
10x Genomics
TXG
$5.55B
$18.1M 0.26%
324,746
– –
MRSN
83
DELISTED
Mersana Therapeutics
MRSN
$17.2M 0.24%
208,777
+36,792
+21% +$5.38M
WVE icon
84
Wave Life Sciences
WVE
$1.12B
$16.4M 0.23%
4,494,458
– –
SRRK icon
85
Scholar Rock
SRRK
$6.33B
$16.1M 0.23%
2,140,025
– –
ILMN icon
86
Illumina
ILMN
$28.2B
$15.8M 0.22%
86,379
-15,657
-15% -$3.17M
CSTL icon
87
Castle Biosciences
CSTL
$733M
$15.4M 0.22%
1,124,043
+175,165
+18% +$3.55M
DOCS icon
88
Doximity
DOCS
$3.87B
$15.3M 0.22%
448,579
– –
CI icon
89
Cigna
CI
$74.5B
$14.1M 0.2%
50,399
-3,077
-6% -$801K
VRNA
90
DELISTED
Verona Pharma
VRNA
$12.1M 0.17%
572,315
+309,632
+118% +$6.6M
REGN icon
91
Regeneron Pharmaceuticals
REGN
$70.9B
$11.7M 0.17%
16,327
+1,011
+7% +$779K
PNT
92
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$11.4M 0.16%
+1,256,197
New +$11.1M
NTRA icon
93
Natera
NTRA
$38.9B
$11.3M 0.16%
232,775
– –
TDOC icon
94
Teladoc Health
TDOC
$1.7B
$9.93M 0.14%
392,264
-40,457
-9% -$1.02M
BAX icon
95
Baxter International
BAX
$11.7B
$9.72M 0.14%
213,434
-60,180
-22% -$2.62M
GILD icon
96
Gilead Sciences
GILD
$167B
$8.68M 0.12%
112,650
+12,294
+12% +$981K
BIIB icon
97
Biogen
BIIB
$30.4B
$7.29M 0.1%
25,598
+894
+4% +$266K
AZN icon
98
AstraZeneca
AZN
$262B
$6.13M 0.09%
42,800
+7,000
+20% +$1.03M
AMGN icon
99
Amgen
AMGN
$198B
$6.06M 0.09%
27,310
-11,057
-29% -$2.57M
ESPR
100
DELISTED
Esperion Therapeutics
ESPR
$5.85M 0.08%
4,208,264
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2023 Portfolio in Review

As of Q2 2023, Bellevue Group held 168 positions worth $7.01B, up 1.7% from $6.89B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group's Q2 2023 filing shows 9 new, 52 increased, 52 reduced and 12 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M. The largest sale was Sarepta Therapeutics, an estimated $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2023 buy was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M.
  • Bellevue Group added most to Evolent Health in Q2 2023, an estimated $40.7M increase.
  • Bellevue Group's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $57.6M.
  • Bellevue Group fully exited Pfizer in Q2 2023, selling an estimated $30.2M.
  • Bellevue Group's ten largest holdings make up 37% of its $7.01B portfolio in Q2 2023.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2023.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $7.01B.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.